We would love to hear your thoughts about our site and services, please take our survey here.
Yes, spreadex are hedging against the difference between their positive and negative open positions, as/when they close, the equivalent shares will be sold. Have seen it before, a few years ago, someone took a big spreadex bet on an AIM stock, they lost out, think it was Alba minerals, but not so sure now.
This looks very lucrative
Starting from 2024, a new revenue segment called Private label will be introduced to the Group, referring to products manufactured by VLG-owned factories, which develop formulations for retailers, who will sell these products through their own retail channels. This is aimed at providing a more comprehensive understanding of our business performance by segregating these revenues from the currently reported segments. As revenue from this segment grows, the Group will consider reporting and disclosing performance separately in future periods.
Customer Brands refers to products manufactured by VLG-owned factories, which co-develop formulations with customers, who will distribute and market these products under their own brand names
Dug, for sure, insider trading is a thing that goes on, and in my opinion, it's rife on AIM, the big trick though is proving it! All private investors have got to go on is suspicion flagged up by coincidence, how many times do you see an increase in volume and share price just before good news is announced! The situation here though, Diggle sold shares before the poor trading update was announced, so was that just a lucky coincidence, or was someone in the know, investors will need to make their own mind up on that play, as for proof, no one on the outside will have any.
Apart from treating private investors with contempt, they must also think we are stupid and unable to remember what was said. "Word of mouth was going to sell CiRT" Because medical professionals have heard it all before from sales people.
@ DugWalker, "one critical sales person took leave of absence" yes Dug, that's basically what they said, LOL, I'm not buying that explanation though, It just doesn't make sense to me, an oncologist who has used the test and is happy with the results will not need to be enticed by a salesperson to buy again, he/her would repete buy because it was useful, also by recommendation, enlighten other about the test in their field. The company said, word of mouth was going to sell the product! So with one sales guy out, you would expect a bit of a slowdown in growth, or at worse, sales to be flat until he is back, but a declin, that's something else.
I agree Dug, the transform trial is a massive validation trial for the PSE test, OBD should at least offer the test at cost price, or are they worried about the claimed 94% accuracy might not stand up to scrutiny!
Serendipity, that's what I thought when I invested here, (then proceed to lose 10K) was that medical insurance would pay the price! But It's not happening.
I also would pay for the PSE test as a choice, rather than have a biopsy, my point was: The average person in a good state of health is not going to pay £750 for the test, they may do, if, after having a cheap PSA test that has flagged up a problem.
I don't know much about medical insurance in america, but I do know if you start making claim on house/car insurance in the UK the price goes up, also something similar with pet insurance, as the dog gets older, the price goes up.
Folk are not going to pay £750 for an annual checkup PSE test, maybe they will pay it if something sinister has been flagged!
Also, over two grand for the CiRT test is a lot of money, seems to me, It's priced to take advantage, bit like the top heavy management running this company.